My Portfolio
+
LINK YOUR PORTFOLIO

NRX Pharmaceuticals Inc NRXP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:31 PM EDT
4.07quote price arrow up+0.02 (+0.49%)
Volume
14,422
Close
4.05quote price arrow down-0.57 (-12.34%)
Volume
4,253,665
52 week range
1.62 - 5.06
Loading...
  • Open3.61
  • Day High4.29
  • Day Low3.45
  • Prev Close4.62
  • 52 Week High5.06
  • 52 Week High Date06/02/26
  • 52 Week Low1.62
  • 52 Week Low Date03/09/26

Latest On NRX Pharmaceuticals Inc

 

Key Stats

  • Market Cap146.727M
  • Shares Out36.23M
  • 10 Day Average Volume1.69M
  • Dividend-
  • Dividend Yield-
  • Beta2.18

Latest On NRX Pharmaceuticals Inc

 

KEY STATS

  • Open3.61
  • Day High4.29
  • Day Low3.45
  • Prev Close4.62
  • 52 Week High5.06
  • 52 Week High Date06/02/26
  • 52 Week Low1.62
  • 52 Week Low Date03/09/26
  • Market Cap146.727M
  • Shares Out36.23M
  • 10 Day Average Volume1.69M
  • Dividend-
  • Dividend Yield-
  • Beta2.18

RATIOS/PROFITABILITY

  • EPS (TTM)-1.27
  • P/E (TTM)-3.18
  • Fwd P/E (NTM)4.81
  • EBITDA (TTM)-17.018M
  • ROE (TTM)-682.81%
  • Revenue (TTM)2.293M
  • Gross Margin (TTM)50.46%
  • Net Margin (TTM)-1,070.26%
  • Debt To Equity (MRQ)-39.06%

EVENTS

  • Earnings Date08/17/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression...
Jonathan Javitt M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Joseph Casper
Chief Operating Officer
Michael Abrams
Chief Financial Officer and Treasurer
Riccardo Panicucci
Chief Manufacturing and Technology Officer
Address
1201 ORANGE STREET, SUITE 600
Wilmington, DE
19801
United States